EFPIA represents direct membership of 33 national associations and 40 leading pharmaceutical companies; collectively EFPIA provides the voice of 1,900 companies.
With the benefit of hindsight and detailed figures courtesy of qordata EU Compliance AnalyticsTM 3, we can begin to draw three key insights :
1. With the total spend of Euro 2022 billion on medicines across EU in 2017, the relative percentage of spend on HCPs and HCOs by pharmaceutical manufacturers is small. The big five countries (France, UK, Germany, Italy and Spain) collectively spent around €1.9 billion in 2015 and €2 billion in 2016, or around 1% of the total revenue. So, the conclusion is that drug manufacturers are not spending excessive sums of money.
2. Between 2015 and 2016, the spend behavior by the manufacturers has remained relatively unchanged as the reported transfers of value to HCPs and HCOs are evaluated.
The total spend by the big five in EU marginally increased by 3% from €1.9B in 2015 to €2.0B in 2016. Therefore, one could presume that the transparency did not alter drug manufacturer behavior, and they seem comfortable in sharing the spend without altering the amount or nature of it year over year.
3. Between 2015 and 2016, the spend reporting behavior by HCPs and HCOs respectively have shown slight improvements and are at relative ease in sharing the transfer of values.
The total consented amount by HCPs grew from €1.1B in 2015 to €1.3B in 2016 when analyzing Germany, Italy, Spain and UK combined. Similarly, for HCOs, the consented amount grew from €3.6B in 2015 to €4.8B in 2016.
To read the article by By Talha Awan